Treatment of Hyponatremia

Introduction to Hyponatremia

Hyponatremia can be classified into different types, including euvolemic and hypervolemic hyponatremia, with hypervolemic hyponatremia occurring in conditions with increased total body water and sodium, such as cirrhosis with ascites, heart failure, and nephrotic syndrome 1
The diagnosis of SIADH is characterized by hyponatremia (serum sodium <134 mEq/L), inappropriately high urine osmolality (>300 mOsm/kg), and elevated urinary sodium concentration (>40 mEq/L) 2

The American Association for the Study of Liver Diseases recommends assessing volume status through physical examination and laboratory tests, including serum and urine osmolality, urine sodium concentration, and medication history review, to diagnose hyponatremia 3
Hyponatremia can be classified into three categories based on severity:
Severity Sodium Level
Mild 126-135 mEq/L
Moderate 120-125 mEq/L
Severe <120 mEq/L

The American Association for the Study of Liver Diseases recommends fluid restriction to 1,000 mL/day as the primary strategy for moderate cases of euvolemic hyponatremia, and more severe restriction along with albumin infusion for severe cases (<120 mEq/L) 5
For patients with euvolemic hyponatremia, consideration should be given to reducing or suspending diuretics if the patient is currently receiving them, with monitoring of serum sodium levels every 4-6 hours during active correction 5
Moderate salt restriction (5-6.5 g/day, equivalent to 87-113 mmol sodium) is recommended for patients with cirrhosis and hypervolemic hyponatremia, along with nutritional counseling on sodium content in diet, according to the American Association for the Study of Liver Diseases 1
Combination therapy with spironolactone and furosemide may be used cautiously in patients with recurrent severe ascites, with close monitoring for adverse events, as suggested by the European Society of Cardiology 1
The American Heart Association suggests considering vaptans (vasopressin receptor antagonists) such as tolvaptan for persistent hyponatremia, particularly effective in SIADH, heart failure, and liver cirrhosis 3
The European Society of Cardiology recommends using loop diuretics in edematous hyponatremic states, with careful monitoring to avoid overly rapid correction 1

The following treatment approaches are recommended for hyponatremia in cirrhosis:

Target correction rate of 4-6 mEq/L in 24 hours, not exceeding 8 mEq/L/day to prevent osmotic demyelination syndrome, as recommended by the American Heart Association 1
Serum sodium levels should be monitored every 4-6 hours during active correction, and fluid status and neurological status should be regularly assessed, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1
Overly rapid correction of hyponatremia can lead to osmotic demyelination syndrome, which typically presents 2-7 days after rapid correction 5
During treatment of hypervolemic hyponatremia, monitor serum sodium levels every 4-6 hours during active correction, assess fluid status, and evaluate neurological status for signs of ODS (dysarthria, dysphagia, oculomotor dysfunction, quadriparesis) 5

Hyponatremia in cirrhosis is associated with increased risk of hepatic encephalopathy, hepatorenal syndrome, and spontaneous bacterial peritonitis, emphasizing the importance of proper management 5
Overly rapid correction of hyponatremia can lead to osmotic demyelination syndrome, and hypertonic saline misuse can worsen edema and ascites in hypervolemic states, as warned by the European Society of Intensive Care Medicine 1
Excessive fluid restriction may be poorly tolerated by patients, and failure to address the underlying cause of hypervolemic state (e.g., heart failure, cirrhosis) can lead to inadequate treatment, as noted by the American College of Cardiology 1
The National Institute of Diabetes and Digestive and Kidney Diseases recommends monitoring for adverse effects of tolvaptan, including thirst, dry mouth, and polyuria, and being aware of the increased risk of gastrointestinal bleeding in patients with cirrhosis 1